DelveInsight’s, “Frontotemporal Dementia Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Frontotemporal Dementia Emerging drugs, the Frontotemporal Dementia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Frontotemporal Dementia pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Frontotemporal Dementia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Frontotemporal Dementia clinical trials studies, Frontotemporal Dementia NDA approvals (if any), and product development activities comprising the technology, Frontotemporal Dementia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Frontotemporal Dementia Pipeline Report

 

• DelveInsight’s Frontotemporal Dementia Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.

 

• The leading Frontotemporal Dementia Companies include Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG  and others.

 

• Promising Frontotemporal Dementia Pipeline Therapies include AL001, TPN-101, PBFT02, PR006, DNL593 (PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.

 

• The Frontotemporal Dementia companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The Frontotemporal Dementia pipeline therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia.

 

Request a sample and discover the recent breakthroughs happening in the Frontotemporal Dementia Pipeline landscape @ Frontotemporal Dementia Pipeline Outlook Report

 

Frontotemporal Dementia Overview

Frontotemporal dementia is an uncommon type of dementia that causes problems with behaviour and language. Dementia is the name for problems with mental abilities caused by gradual changes and damage in the brain. Frontotemporal dementia affects the front and sides of the brain (the frontal and temporal lobes).Dementia mostly affects people over 65, but frontotemporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, frontotemporal dementia tends to develop slowly and get gradually worse over several years.

 

Recent Developmental Activities in the Frontotemporal Dementia Treatment Landscape

 

• In February 2022, Arkuda Therapeutics, announced the completion of a $64 million Series B financing. The financing was co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital (a Citadel company), and Eli Lilly and Company, as well as existing investors Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.

 

• In January 2022, The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced that they have partnered to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).

 

• In October 2021, Libra Therapeutics, Inc. announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more than 25 years of drug discovery and development expertise in the areas of neuroscience, metabolic, inflammatory, and orphan diseases and a neuroscientist by training, Dr. Lambert will lead Libra’s development of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

 

• In July 2021, GlaxoSmithKline plc and Alector entered into a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.

 

• In July 2021, Muna Therapeutics announced the successful closing of a USD 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventures, and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures, and VIB joining the round. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. 

 

For further information, refer to the detailed Frontotemporal Dementia Drugs Launch, Frontotemporal Dementia Developmental Activities, and Frontotemporal Dementia News, click here for Frontotemporal Dementia Ongoing Clinical Trial Analysis

 

Frontotemporal Dementia Emerging Drugs Profile

 

• PR 006 : Prevail Therapeutics

PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.

 

• Latozinemab : Alector

AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.

 

• PBFT 02 : Passage Bio

Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia.

 

• WVE 004 : WaVe life Sciences

WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.

 

• EXO 050 : Coya Therapeutics

EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD.Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD.  

 

Frontotemporal Dementia Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

 

Find out more about the Frontotemporal Dementia Pipeline Segmentation, Therapeutics Assessment, and Frontotemporal Dementia Emerging Drugs @ Frontotemporal Dementia Treatment Landscape

 

Scope of the Frontotemporal Dementia Pipeline Report

 

• Coverage- Global

 

• Frontotemporal Dementia Companies- Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4, Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG, and others.

 

• Frontotemporal Dementia Pipeline Therapies- AL001, TPN-101, PBFT02, PR006, DNL593(PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102,  SOL-257, and others.

 

• Frontotemporal Dementia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Frontotemporal Dementia Pipeline Companies and Therapies, click here @ Frontotemporal Dementia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Frontotemporal Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Frontotemporal Dementia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Latozinemab : Alector
12. Drug profiles in the detailed report…..
13. Mid Stage Products (PhaseI/ II)
14. PR 006 : Prevail Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EXO 050 : Coya Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Frontotemporal Dementia Key Companies
21. Frontotemporal Dementia Key Products
22. Frontotemporal Dementia – Unmet Needs
23. Frontotemporal Dementia – Market Drivers and Barriers
24. Frontotemporal Dementia – Future Perspectives and Conclusion
25. Frontotemporal Dementia Analyst Views
26. Frontotemporal Dementia Key Companies
27. Appendix

 

Got Queries? Find out the related information on Frontotemporal Dementia Mergers and acquisitions, Frontotemporal Dementia Licensing Activities @ Frontotemporal Dementia Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/